Nanogen's Q2 Revenues Spike 63 Percent, Loss Widens on Consolidation Costs | GenomeWeb
NEW YORK (GenomeWeb News) - Nanogen yesterday said second-quarter revenues increased 63 percent as R&D spending increased 15 percent and its net loss increased 3 percent.
 
Total receipts for the three months ended June 30 increased to $10.3 million from $6.3 million year over year.
 
The company said product-related revenue rose 32 percent to $5.3 million from $4 million, and income from licensing and royalties increased 13 percent to $2.1 million from $1.8 million.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.